# Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis

> **NCT02487407** · PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 66 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ODM-109
- **DRUG:** Placebo for ODM-109

## Key facts

- **NCT ID:** NCT02487407
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-05
- **Final completion:** 2017-06
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2017-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487407, "Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02487407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*